Bio-View Ltd (BIOV) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Bio-View Ltd ILS 0.41, price ILS 0.78, upside -47.4%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bio-View Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 0.7100 ILA – 464.80 ILA · fair‑value band 0.2700 ILA – 0.5100 ILA · the 0.7790 ILA price screens above the 0.4100 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Bio-View in your weekly email
Every Wednesday you see whether Bio-View is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally.
Show more
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an automated imaging system that supports multiple applications; Encore, an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation that streamlines review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was incorporated in 1998 and is headquartered in Rehovot, Israel.
Stock analysis
Bio-View Ltd (BIOV) currently trades at 0.7790 ILA, while our model-based Fair Value estimate is 0.4100 ILA, implying the stock looks roughly 90.0% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 0.2700 ILA (bear) to 0.5100 ILA (bull), the price of 0.7790 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Bio-View Ltd reported revenue of 19.9M ILS in FY2025 versus 30.5M ILS in FY2021, a compound −10.1%/yr. Reported net income was −15.3M ILS in FY2025.
Key figures
Market cap 12.2M ILA · P/S ratio 0.61 · EPS (TTM) −1.13 ILA · Net margin −76.9% · Return on equity −94.8% · Return on assets (EBIT) −7.2% · Operating margin −26.2% · Revenue (TTM) 19.9M ILA.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −47%, BIOV screens richer than that median.
Fair Value models
Bear 0.2700 ILAFair Value 0.4100 ILABull 0.5100 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−22.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.1%
Start year 2020 (pandemic). Over 10 years: −5.3% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.6% (2020) → −39.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−48% · Below median
Profitability
Return on assets−18% · Bottom 25%
Net margin (TTM)−77% · Bottom 25%
Operating margin (TTM)−26% · Bottom 25%
Growth and dividend
Revenue growth24% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.43× · Cheapest 25%
P/S (TTM)0.20× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bio-View Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BIOV
Frequently asked questions
Is Bio-View Ltd (BIOV) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 0.4100 ILA versus a price of 0.7790 ILA, about −47% upside (overvalued).
What is the fair value of BIOV?
Our model-based fair value for Bio-View Ltd is 0.4100 ILA (as of Sep 23, 2026), built from audited fundamentals. The current price: 0.7790 ILA.
What is the quality score of BIOV?
Bio-View Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-View Ltd (BIOV)?
Our model-based price target is the fair value of 0.4100 ILA (as of Sep 23, 2026) from 1 valuation models. Cautious scenario 0.2700 ILA, optimistic scenario 0.5100 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-View Ltd stock forecast for 2026?
Our models put fair value at 0.4100 ILA, about −47% upside versus a price of 0.7790 ILA (overvalued). Cautious scenario 0.2700 ILA, optimistic scenario 0.5100 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-View Ltd (BIOV)?
Bio-View Ltd reported trailing-twelve-month revenue of about 19.9M ILS (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Bio-View Ltd (BIOV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-View Ltd it is 0.4100 ILA per share (as of Sep 23, 2026), against a price of 0.7790 ILA. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Bio-View Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BIOV trades above its calculated fair value: price 0.7790 ILA, fair value 0.4100 ILA, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOV?
No. The price is what the market pays today (0.7790 ILA); the fair value is what the company's own numbers justify (0.4100 ILA). For Bio-View Ltd the two are 0.3690 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-View Ltd worth?
The market values Bio-View Ltd at about 12.2M ILA (market capitalisation, as of Sep 23, 2026). Per share that is 0.7790 ILA; our models calculate a fair value of 0.4100 ILA per share.
What do the bullish and bearish scenarios say about BIOV?
Our models span a range for Bio-View Ltd: cautious scenario 0.2700 ILA, base 0.4100 ILA, optimistic 0.5100 ILA per share (as of Sep 23, 2026, price 0.7790 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bio-View Ltd (BIOV)?
Balance-sheet figures for Bio-View Ltd (as of Sep 23, 2026): return on equity −94.8%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is BIOV from its 52-week high?
Bio-View Ltd trades at 0.7790 ILA, about 61% below its 52-week high of 2.00 ILA and 10% above the low of 0.7100 ILA (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.4100 ILA is for.
Which stocks are comparable to Bio-View Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-View Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price 0.7790 ILA, calculated fair value 0.4100 ILA (−47%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOV calculated?
We run Bio-View Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.4100 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Bio-View Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-View Ltd (BIOV)?
The closing price on Sep 24, 2026 was 0.7790 ILA. Our model-based fair value is 0.4100 ILA, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-View Ltd right now?
The price sits above even our optimistic bull case (0.5100 ILA). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.2700 ILA to 0.5100 ILA) leaves room in how you read the outcome.
Key figures of Bio-View Ltd
How large is the market capitalisation of Bio-View Ltd (BIOV)?
The market capitalisation of Bio-View Ltd is 12.2M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-View Ltd (BIOV)?
The price-to-sales ratio of Bio-View Ltd is 0.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bio-View Ltd (BIOV)?
Earnings per share at Bio-View Ltd are −1.13 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bio-View Ltd (BIOV)?
The net margin of Bio-View Ltd is −76.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-View Ltd (BIOV)?
The return on equity (ROE) of Bio-View Ltd is −94.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-View Ltd (BIOV)?
On an EBIT basis the return on assets of Bio-View Ltd is −7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-View Ltd (BIOV)?
The operating margin of Bio-View Ltd is −26.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-View Ltd (BIOV)?
Revenue at Bio-View Ltd is growing +23.8% versus a year earlier (3y avg −11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bio-View Ltd (BIOV)?
Earnings per share at Bio-View Ltd are growing +30.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bio-View Ltd (BIOV) generate?
The free cash flow of Bio-View Ltd is −3.1M ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bio-View Ltd (BIOV) hold?
Bio-View Ltd holds more cash than debt, 2.1M ILA net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Bio-View Ltd in the live analysis
One click puts Bio-View Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
